Anzeige
Mehr »
Freitag, 10.04.2026 - Börsentäglich über 12.000 News
Research Capital bestätigt $3,00 Kursziel - FUTR zündet die nächste Stufe: Vom Fintech zur globalen Finanzplattform
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41HZS | ISIN: US50180M1080 | Ticker-Symbol:
NASDAQ
09.04.26 | 22:00
26,290 US-Dollar
+1,35 % +0,350
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
LB PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
LB PHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur LB PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoLB PHARMACEUTICALS INC - S-1, General form for registration of securities-
27.03.LB Pharmaceuticals presents LB-102 cognitive data at SIRS meeting2
27.03.LB Pharmaceuticals legt positive kognitive Daten für Schizophrenie-Wirkstoff LB-102 vor1
27.03.LB Pharmaceuticals Inc: LB Pharmaceuticals Presents New Analysis from the Phase 2 NOVA-1 Trial Highlighting LB-102's Potential Impact on Cognitive Performance at the 2026 Annual Congress of the Schizophrenia International Research Society ...2
27.03.Stifel hebt Kursziel für LB Pharmaceuticals auf 40 US-Dollar an-
LB PHARMACEUTICALS Aktie jetzt für 0€ handeln
27.03.Stifel raises LB Pharmaceuticals stock price target to $401
26.03.LB PHARMACEUTICALS INC - S-8, Securities to be offered to employees in employee benefit plans1
26.03.LB Pharmaceuticals Inc GAAP EPS of -$0.451
26.03.LB PHARMACEUTICALS INC - 10-K, Annual Report1
26.03.LB Pharmaceuticals Inc: LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update1.341Reported positive results from potentially registrational Phase 2 trial ofLB-102 in schizophrenia Advanced LB-102 into late-stage development in multiple indications with initiation ofa pivotal Phase...
► Artikel lesen
26.03.LB PHARMACEUTICALS INC - 8-K, Current Report1
25.03.LB Pharmaceuticals starts phase 3 trial for schizophrenia drug1
25.03.LB Pharmaceuticals Inc: LB Pharmaceuticals Initiates Pivotal Phase 3 Trial (NOVA-2) for LB-102 in Patients with Schizophrenia1.064LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NOVA-2 trial to enroll approximately 460 patients Primary endpoint to evaluate change in PANSS total score at...
► Artikel lesen
10.03.LB PHARMACEUTICALS INC - 8-K, Current Report2
09.03.LB Pharmaceuticals Inc: LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors791NEW YORK, March 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia...
► Artikel lesen
04.03.LB Pharmaceuticals Inc: LB Pharmaceuticals to Participate in Upcoming March Investor Events1
10.02.LB Pharmaceuticals Inc: LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)1
05.02.LB Pharmaceuticals stock rises on $100M financing1
05.02.LB PHARMACEUTICALS INC - 8-K, Current Report1
05.02.LB Pharmaceuticals Inc: LB Pharmaceuticals Announces $100.0 Million Private Placement432NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia...
► Artikel lesen
Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1